Chinese FDA approves GSK's cervical cancer vaccine Cervarix

19 July 2016

UK pharma major GlaxoSmithKline (LSE: GSK) has received approval for its cervical cancer vaccine Cervarix from the Chinese Food and Drug Administration.

It will be the first human papillomavirus (HPV) types 16 and 18 vaccine against cervical cancer approved to enter the Chinese market, and has the potential to save the lives of millions of girls and women.

Cervarix is already in use in more than 100 other countries and has been approved to be received by girls and women between nine and 25 years old in China, where commercial launch is expected early next year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK